Cellectis (NASDAQ:CLLS) Raised to Strong-Buy at Clear Str

Cellectis (NASDAQ:CLLS) was upgraded by Clear Str to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

CLLS has been the topic of a number of other reports. Barclays raised their target price on shares of Cellectis from $4.00 to $8.00 and gave the company an “overweight” rating in a research note on Friday, October 17th. Wall Street Zen raised Cellectis to a “hold” rating in a research report on Saturday, September 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a report on Wednesday, October 8th. Finally, Wells Fargo & Company restated a “positive” rating and issued a $4.00 price objective on shares of Cellectis in a research note on Monday, October 20th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $6.00.

Cellectis Stock Performance

Cellectis stock opened at $4.83 on Tuesday. The firm’s 50 day moving average price is $4.21 and its two-hundred day moving average price is $3.12. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.49 and a current ratio of 1.49. Cellectis has a 1 year low of $1.10 and a 1 year high of $5.48.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings results on Friday, November 7th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.11. Cellectis had a negative return on equity of 51.22% and a negative net margin of 58.06%.The business had revenue of $37.16 million during the quarter, compared to analyst estimates of $8.22 million. Sell-side analysts forecast that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellectis

Hedge funds have recently bought and sold shares of the company. Delaney Dennis R bought a new position in Cellectis during the 3rd quarter worth about $68,000. Virtu Financial LLC acquired a new position in shares of Cellectis during the 3rd quarter worth about $72,000. OLD Mission Capital LLC bought a new stake in shares of Cellectis in the 1st quarter valued at about $31,000. Acadian Asset Management LLC lifted its position in shares of Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 26,461 shares during the last quarter. Finally, Millennium Management LLC boosted its position in Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 22,080 shares during the period. 63.90% of the stock is currently owned by institutional investors and hedge funds.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.